Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants

About this Study

To evaluate long-term efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group, as assessed by chronic respiratory morbidity (CRM) outcomes.

Sponsor Protocol ID:SHP607-203
IRB Number:2020V0107
Actively Enrolling
Interventional
Phase 2
December 16, 2021
Eligibility Criteria
Both Male and Female
No
Yes
No

Inclusion CriteriaSubjects must meet all of the criteria below: 

1. Subject was randomized into Study SHP607-202. Subjects who were randomized, but did not complete Study SHP607-202 must be at least 12 months CA. 

2. Written informed consents (and assents, if applicable) must be signed and dated by the subject's parent(s)/legally authorized representative(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC). 

Exclusion CriteriaSubjects are excluded from the study if the subject or subject’s parent(s)/legally authorized representative(s) is/are unable to comply with the protocol or is/are unlikely to be available for long-term follow-up as determined by the investigator.

Categories Click category to view its trials.
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Chelsea Giachelli
Phone Number: 601-984-1000
Email: cgiachelli@umc.edu
Principal Investigator:Bhatt, Abhay, M.D.
How to participate in our Clinical Trials